Potency Assay Issues Delayed US FDA Approval Of Mesoblast’s Ryoncil For Years

 
• By Sue Sutter
  
Ryoncil CMC story
Mesoblast's potency assays drew the FDA's attention. (Nancy Pham)

More from Drug Review Profiles

More from Advanced Technologies